相关实验视频

Updated: Jan 18, 2026

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

生物仿真纳米载体用于治疗和管理肠道炎症

Rupam Bera¹, Shivam Pathak¹, Pradhi Srivastava¹

¹Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector-125, Noida 201313, India.

International journal of pharmaceutics: X

|September 8, 2025

概括

生物仿真纳米载体为治疗肠道炎症提供了一种新的方法,包括炎症性肠病. 这些细胞膜涂层的纳米粒子在临床前研究中显示出有望的有针对性传递和降低毒性.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
胃肠病学胃肠病学

背景情况:

肠道炎症,包括炎症性肠病 (IBD),由于慢性和当前治疗方法的局限性, presents显著的临床挑战.
像皮质类固醇和生物药物等常规治疗方法的疗效和副作用有限.
生物仿真纳米载体,利用自然细胞膜,为在肠道炎症中向药物输送提供了一个有希望的策略.

研究的目的:

批判性地检查生物仿真纳米载体的应用作为肠道炎症的精密治疗方法.
审查生物模拟纳米载体开发的制造技术和生物来源.
在肠道炎症的临床前模型中评估仿生纳米载体的潜力.

主要方法:

诸如挤出,超声波和微流体等制造技术用于用细胞膜 (巨细胞,中性粒细胞,血小板,干细胞,细菌) 涂层合成纳米载体.
利用细胞膜固有的生物功能来逃避免疫,准炎症的内皮,并响应炎症刺激.
在临床前研究中评估抑制炎症途径 (NF-κB,NLRP3),细胞因子封存,粘膜愈合,肠道微生物群恢复和全身毒性的评估.

主要成果:

在临床前模型中,生物仿真纳米载体有效抑制了促炎途径和隔离的细胞因子.
这些纳米载体促进了粘膜的愈合,恢复了肠道微生物群的平衡.
观察到最小的系统性毒性,表明在临床前环境中具有良好的安全性.

结论:

生物仿真纳米载体显示出作为肠道炎症的精密治疗药物的巨大潜力,提供疾病修饰能力.
临床翻译需要解决标准化,生物安全和监管方面的挑战.
未来的进展需要跨学科的合作,以优化药理动力学,准和个性化设计.

关键词:

生物模拟学是一种生物模拟学.炎症性肠病是一种炎症性肠病.纳米载体纳米载体是什么纳米医学是一种纳米医学.有针对性的交付目标.性结肠炎是一种

更多相关视频

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...